Gene Solutions plans $100M Hong Kong IPO as early as 2Q27

Gene Solutions plans to raise about $100 million through a Hong Kong IPO as early as 2Q27, Bloomberg reported.

The Vietnam-based genetic testing startup is currently in the pre-listing stage and expects to complete a $50 million Series C financing round by the end of the third quarter, the report said, citing people familiar with the matter.

Gene Solutions targets a listing window between 2Q27 and 3Q27. The company did not disclose its proposed ticker, offer price range, or lead underwriters for the IPO.

The IPO would mark one of the few Southeast Asian healthcare listings in Hong Kong in recent years. The pricing will give the company a valuation that investors will compare against listed genetic testing peers such as BGI Genomics and Myriad Genetics. First-day trading, expected no earlier than mid-2027, will test institutional demand for Southeast Asian healthcare names in the Hong Kong market.

This article is for informational purposes only and does not constitute investment advice.